MorphoSys AG (WBO:MOR) Total Stockholders Equity : €49.0 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Total Stockholders Equity?

MorphoSys AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €49.0 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. MorphoSys AG's Book Value per Share for the quarter that ended in Dec. 2023 was €1.30. The ratio of a company's debt over equity can be used to measure how leveraged this company is. MorphoSys AG's Debt-to-Equity for the quarter that ended in Dec. 2023 was 12.97.

MorphoSys AG Total Stockholders Equity Historical Data

The historical data trend for MorphoSys AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Total Stockholders Equity Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

394.70

621.32

244.88

157.41

49.05

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															157.41	97.03	31.67	-	49.05

MorphoSys AG (WBO:MOR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

MorphoSys AG's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(49.049	-	0)	/	37.6015
	=	1.30

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

MorphoSys AG's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14.051	+	621.882)	/	49.049
	=	12.97

MorphoSys AG Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.